C4 Therapeutics (CCCC) stock price is $2.89, down 3.67% on the day, as of Nov 11, 2026. It has a market cap of $393.93Mn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap393.93 Mn
P/E-4.48
FCF (Yr)-99.30 Mn
ROA (Yr)-29.63
EV to EBIT5.39
Net Income (Yr)-105.00 Mn
Enterprise Value-549.34 Mn
Add ratio to table…
About
C4 Therapeutics is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines. Leveraging its proprietary TORPEDO platform, the company designs and optimizes oral bioavailable protein degraders that harness the cell’s natural ubiquitin-proteasome system to eliminate disease-causing proteins. Its pipeline includes oncology candidates for multiple myeloma and non-small…
C4 Therapeutics is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines. Leveraging its proprietary TORPEDO platform, the company designs and optimizes oral bioavailable protein degraders that harness the cell’s natural ubiquitin-proteasome system to eliminate disease-causing proteins. Its pipeline includes oncology candidates for multiple myeloma and non-small cell lung cancer, as well as early-stage programs targeting inflammation, neuroinflammation and neurodegeneration.
C4 Therapeutics generates revenue primarily through collaboration and licensing agreements with pharmaceutical partners. These arrangements provide upfront cash payments, research funding, milestone payments tied to development, regulatory and sales achievements, and tiered royalties on net sales of any resulting products. Current collaborations include agreements with Pfizer for clinical trial supply, Merck KGaA for oncology target discovery, Roche for various target programs, Betta Pharma for development of an EGFR degrader in Greater China, and Biogen for immunology-related degrader programs. The company has not yet commercialized any product and therefore does not derive revenue from product sales.
Within the emerging targeted protein degradation sector, C4 Therapeutics competes with other biotechnology firms such as Arvinas and several academic and pharmaceutical entities pursuing similar modalities. Its competitive advantage lies in the TORPEDO platform, which enables rational design of degraders with desired properties including oral bioavailability, blood-brain barrier penetration and catalytic activity. The platform’s focus on the Cereblon E3 ligase, supported by a proprietary library of Cereblon binders, aims to improve degrader efficiency and selectivity compared to traditional inhibitors. Additionally, the company’s ability to advance both mono‑ and bis‑specific degraders expands its target range beyond that achievable with conventional small‑molecule approaches.
The company’s prospective customers are patients suffering from relapsed or refractory multiple myeloma, non-small cell lung cancer with EGFR mutations, and individuals with inflammatory, neuroinflammatory or neurodegenerative disorders. Until therapies receive regulatory approval, C4 Therapeutics works closely with collaboration partners such as Pfizer, Merck KGaA, Roche, Betta Pharma and Biogen, who fund research and development efforts and may eventually commercialize the resulting medicines in their respective territories.
Sector:HealthcareSector rationaleC4 Therapeutics is a clinical-stage biopharmaceutical company that designs small-molecule medicines and protein degraders for oncology and neurodegenerative diseases. Its revenue is derived from collaboration and licensing agreements with pharmaceutical partners like Pfizer and Roche to develop these medical treatments.Industry:BiotechnologyBiotechnologyPrimaryC4 Therapeutics is a clinical-stage biopharmaceutical company that develops therapies derived from biological science, specifically targeted protein degradation using its TORPEDO platform. Its revenue is currently derived from collaboration and milestone payments from partners like Pfizer, Merck KGaA, and Roche, which is characteristic of biotechnology developers.Classified using BQ-MICSCIK: 0001662579
Bull & bear
Investment Thesis
▲ Bull case
C4 Therapeutics (CCCC) has secured a potentially transformative partnership with Roche focused on the research and development of targeted protein degradation therapies, specifically leveraging its TORPEDO platform to develop novel cancer drugs. This deal structure, which could exceed $1 billion in total value including milestones and royalties, provides significant non-dilutive funding that de-risks CCCC’s pipeline advancement while validating the scientific credibility of its approach in the eyes of a major pharmaceutical partner. The collaboration allows CCCC to retain commercial rights in key markets, preserving upside potential if candidates progress successfully, and reduces near-term cash burn pressure, which is critical given the company’s historical reliance on external financing. By aligning with Roche’s extensive oncology expertise and global development infrastructure, CCCC gains access to resources that could accelerate clinical timelines and improve the probability of technical success for its pipeline assets, particularly in hard-to-treat indications where targeted protein degradation has shown promise.
The partnership with Roche represents a structural shift in how CCCC is perceived within the biotech landscape, moving it from a speculative early-stage platform company to a validated collaborator with big-pharma credibility, which could significantly lower its cost of capital and improve investor sentiment over time. Unlike transient market optimism driven by single data points, this deal is rooted in a multi-year research agenda that suggests sustained value creation potential, with milestones tied to preclinical and clinical progression rather than binary events. Management’s decision to pursue such a broad R&D collaboration—rather than a narrow licensing deal—indicates confidence in the scalability of their platform across multiple targets, a point that may be underappreciated by the market focused solely on near-term catalysts. Furthermore, the absence of a recent earnings call means there is no quarterly performance distraction, allowing the market to focus on this long-term strategic development as a primary valuation driver.
C4 Therapeutics (CCCC) has secured a potentially transformative partnership with Roche focused on the research and development of targeted protein degradation therapies, specifically leveraging its TORPEDO platform to develop novel cancer drugs. This deal structure, which could exceed $1 billion in total value including milestones and royalties, provides significant non-dilutive funding that de-risks CCCC’s pipeline advancement while validating the scientific credibility of its approach in the eyes of a major pharmaceutical partner. The collaboration allows CCCC to retain commercial rights in key markets, preserving upside potential if candidates progress successfully, and reduces near-term cash burn pressure, which is critical given the company’s historical reliance on external financing. By aligning with Roche’s extensive oncology expertise and global development infrastructure, CCCC gains access to resources that could accelerate clinical timelines and improve the probability of technical success for its pipeline assets, particularly in hard-to-treat indications where targeted protein degradation has shown promise.
The partnership with Roche represents a structural shift in how CCCC is perceived within the biotech landscape, moving it from a speculative early-stage platform company to a validated collaborator with big-pharma credibility, which could significantly lower its cost of capital and improve investor sentiment over time. Unlike transient market optimism driven by single data points, this deal is rooted in a multi-year research agenda that suggests sustained value creation potential, with milestones tied to preclinical and clinical progression rather than binary events. Management’s decision to pursue such a broad R&D collaboration—rather than a narrow licensing deal—indicates confidence in the scalability of their platform across multiple targets, a point that may be underappreciated by the market focused solely on near-term catalysts. Furthermore, the absence of a recent earnings call means there is no quarterly performance distraction, allowing the market to focus on this long-term strategic development as a primary valuation driver.
Despite the headline-grabbing potential value of the Roche deal, C4 Therapeutics (CCCC) remains a pre-revenue company with no approved products and a history of clinical setbacks, most notably the failure of its lead candidate CFT8634 in earlier trials, which raises legitimate concerns about the translatability of its TORPEDO platform to successful patient outcomes. The partnership, while financially supportive, does not guarantee clinical success, and the deferred nature of milestone payments means CCCC will likely continue to rely on additional financing rounds to sustain operations until those triggers are met, potentially leading to shareholder dilution if future capital raises occur at unfavorable valuations. The company’s cash runway, though extended by the upfront and near-term payments from Roche, remains dependent on achieving preclinical and clinical milestones that are inherently uncertain in oncology drug development, where failure rates exceed 90% even for well-validated mechanisms.
Market enthusiasm surrounding the Roche deal may be overlooking the highly competitive and rapidly evolving landscape of targeted protein degradation, where multiple well-funded players—including Arvinas, Kymera Therapeutics, and others—are pursuing similar strategies with broader pipelines or more advanced clinical-stage assets, potentially limiting CCCC’s long-term differentiation and commercial leverage. Furthermore, the lack of detailed financial disclosure in the news release—such as the size of the upfront payment, annual research funding, or equity component—makes it difficult to assess the true immediate financial benefit to CCCC, raising the possibility that the market is overestimating the near-term impact of the deal. Without transparency on these terms, investors cannot accurately model the deal’s contribution to reducing cash burn or extending runway, which is essential for evaluating whether the partnership meaningfully alters the company’s risk profile beyond a reputational boost.
Despite the headline-grabbing potential value of the Roche deal, C4 Therapeutics (CCCC) remains a pre-revenue company with no approved products and a history of clinical setbacks, most notably the failure of its lead candidate CFT8634 in earlier trials, which raises legitimate concerns about the translatability of its TORPEDO platform to successful patient outcomes. The partnership, while financially supportive, does not guarantee clinical success, and the deferred nature of milestone payments means CCCC will likely continue to rely on additional financing rounds to sustain operations until those triggers are met, potentially leading to shareholder dilution if future capital raises occur at unfavorable valuations. The company’s cash runway, though extended by the upfront and near-term payments from Roche, remains dependent on achieving preclinical and clinical milestones that are inherently uncertain in oncology drug development, where failure rates exceed 90% even for well-validated mechanisms.
Market enthusiasm surrounding the Roche deal may be overlooking the highly competitive and rapidly evolving landscape of targeted protein degradation, where multiple well-funded players—including Arvinas, Kymera Therapeutics, and others—are pursuing similar strategies with broader pipelines or more advanced clinical-stage assets, potentially limiting CCCC’s long-term differentiation and commercial leverage. Furthermore, the lack of detailed financial disclosure in the news release—such as the size of the upfront payment, annual research funding, or equity component—makes it difficult to assess the true immediate financial benefit to CCCC, raising the possibility that the market is overestimating the near-term impact of the deal. Without transparency on these terms, investors cannot accurately model the deal’s contribution to reducing cash burn or extending runway, which is essential for evaluating whether the partnership meaningfully alters the company’s risk profile beyond a reputational boost.